Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veraxa Biotech AG - Ordinary Shares (NQ:VRXA)

1.650 UNCHANGED
Streaming Delayed Price Updated: 11:20 AM EDT, Sep 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Veraxa Biotech AG - Ordinary Shares

< Previous 1 2 Next >
BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Bolsters Scientific Leadership Ahead of BiTAC(R) Clinical Development
Via Investor Brand Network
NetworkNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Appoints Raju Willener as Chief Financial Officer
Via Investor Brand Network
News headline image
VERAXA Biotech Appoints Raju Willener as Chief Financial Officer
Mr. Willener brings more than three decades of global capital markets and corporate finance experience to support advancement of the Company’s pipeline of potential best-in-class therapies led by its... 
From Veraxa Biotech AG
Via GlobeNewswire
VERAXA Biotech AG (NASDAQ: VRXA), Secarna Partnership Milestone Opens New Potential Market for Conjugation Technology
Via Investor Brand Network
BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) and Secarna Report Positive Early Results From Antibody Oligonucleotide Collaboration
Via Investor Brand Network
VERAXA Biotech AG (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase
Via Investor Brand Network
Topics Intellectual Property
News headline image
VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance
Successful in vitro proof-of-concept study demonstrates the potential to create novel antibody-oligonucleotide conjugates (AOCs) by combining both parties’ technologies and expertise 
From Veraxa Biotech AG
Via GlobeNewswire
MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Strengthens Clinical Development Path for Next-Gen Cancer Therapy
Via Investor Brand Network
VERAXA Biotech AG (NASDAQ: VRXA) Builds Antibody-Based Cancer Pipeline Around Dual-Targeting Precision
Via Investor Brand Network
Topics Intellectual Property
InvestorNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Turns to AI to Advance Precision Oncology
Via Investor Brand Network
Topics Artificial Intelligence
MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Turns to AI to Advance Precision Oncology
Via Investor Brand Network
Topics Artificial Intelligence
BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Builds Strategic Position in Antibody Therapeutics Market
Via Investor Brand Network
VERAXA Biotech AG (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies
Via Investor Brand Network
Topics Intellectual Property
VERAXA Biotech AG (NASDAQ: VRXA) Strengthens Scientific Leadership as New CSO Takes the Helm in Advancing BiTAC(R) Cancer Therapy Platform
Via Investor Brand Network
InvestorNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Expands Patent Portfolio to Support Next-Generation Cancer Therapy Platforms
Via Investor Brand Network
Topics Intellectual Property
News headline image
VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates
First BiTAC®-related patent applications filed in H1 2026 including patents covering composition of matter and proprietary payload platform, with additional patents secured in contributing technology... 
From Veraxa Biotech AG
Via GlobeNewswire
MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Approve Corporate Governance, Financing Measures
Via Investor Brand Network
BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration
Via Investor Brand Network
News headline image
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
VXA-222 advances into next phase at VERAXA 
From Veraxa Biotech AG
Via GlobeNewswire
News headline image
VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth
From Veraxa Biotech AG
Via GlobeNewswire
NetworkNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officer
Via Investor Brand Network
News headline image
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio
From Veraxa Biotech AG
Via GlobeNewswire
VERAXA Biotech AG (NASDAQ: VRXA) Advances BiTAC(R)-TCE Development with Positive Regulatory Feedback from Germany
Via Investor Brand Network
MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform
Via Investor Brand Network
News headline image
VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan
Scientific Advice from the German Regulatory Authority supports the biological rationale and proposed development approach for VERAXA's BiTAC-TCE technology and product candidate, providing an initial... 
From Veraxa Biotech AG
Via GlobeNewswire
Why VERAXA Biotech AG (NASDAQ: VRXA) Could Benefit More Than Others From AI’s Growing Impact on Drug R&D
Via Investor Brand Network
Topics Artificial Intelligence
InvestorNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Partners With Ardigen to Advance AI-Driven Cancer Drug Development
Via Investor Brand Network
Topics Artificial Intelligence
NetworkNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Appoints Carl von Halem Interim Chief Financial Officer
Via Investor Brand Network
News headline image
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs) 
From Veraxa Biotech AG
Via GlobeNewswire
News headline image
VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister
From VERAXA Biotech GmbH
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.